Скачать или смотреть Pluri’s Chairman on Unlocking Hidden Biotech Value | NYSE Interview with Alejandro Weinstein

https://pluri-biotech.com/ Biotechnology breakthroughs don’t create value unless they reach the market.

From the floor of the New York Stock Exchange, Jane King sits down with Alejandro Weinstein, Chair of the Board of Directors and a major shareholder of Pluri (NASDAQ: PLUR).

Weinstein explains why he views Pluri as a deeply undervalued biotech company — comparing its core technologies to “hidden Picassos” not yet reflected in the stock price. At the center is Pluri’s patented 3D cell expansion platform, which enables scalable, cost-efficient growth of animal, plant, and human cells.

In this conversation, Weinstein outlines a strategic pivot toward commercialization, with a sharp focus on longevity, regenerative and reconstructive medicine using placenta-derived cells and exosomes, alongside next-generation cell agriculture that could redefine food production in a climate-constrained world.

This interview is part of the NYSE Jane King Interviews series.

🔗 Learn more about Pluri:
https://pluri-biotech.com/

🐦 X: https://x.com/Pluribiotech